UniQure has set its sights on submitting its Huntington’s disease gene therapy for approval next year after the asset was ...

When it comes to Cyclerion Therapeutics' colorful backstory, the only consistency has been its inconsistency. | When it comes ...

Lantheus has inked a deal giving GE HealthCare the rights to carry its prostate cancer PET imaging agent in Japan, with the ...

Heartflow has secured a new FDA clearance for its artificial intelligence program to analyze the buildup of dangerous plaques ...

While the average earnout potential per biopharma deal has declined over the last five years, the mean upfront value has been ...

Sparrow Pharmaceuticals is looking to send its potential diabetes treatment soaring through clinical trials with the help of ...

Harmony Biosciences’ $60 million bet on a once-failed Fragile X candidate has gone off the rails. | Harmony Biosciences’ $60 million bet on a once-failed Fragile X candidate has gone off the rails.

Sanofi is bestowing $625 million on its investment arm Sanofi Ventures, seeking to take advantage of a biotech landscape that ...

Rome’s pipeline is built on twin franchises, one composed of reverse transcriptase inhibitors and another pursuing tumor ...

Tuesday morning, Seres confirmed that one of these actions would involve reducing its workforce by 25%. Employees who are ...

Medtronic has announced plans to double the footprint of its London office, focused on developing artificial intelligence and ...

Roche has set its sights on becoming a “top three” obesity company, according to the pharma’s long-awaited strategy for ...